Biosimilars Take The Stage As Regulatory Debate Goes Global (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
With more emerging economies starting to look to biosimilars as a potential source of cost savings on expensive biological medicines, discussions are intensifying over issues such as the regulatory systems used to approve biosimilars, how best to monitor their safety, and what names they should carry.